MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, INBX had -$33,479K decrease in cash & cash equivalents over the period. -$33,834K in free cash flow.

Cash Flow Overview

Change in Cash
-$33,479K
Free Cash flow
-$33,834K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net income (loss)
-35,256 -71,965
Depreciation and amortization
583 1,336
Accretion of debt discount and non-cash interest expense
638 1,159
Stock-based compensation expense
3,175 5,220
Non-cash lease expense
456 878
Loss on disposal of fixed assets
-3 -
Non-cash gain on transaction with acquirer
0 0
Accounts receivable
-127 -119
Other receivables
-3 689
Receivables from related parties
0 -23
Prepaid expenses and other current assets
-25 -952
Other non-current assets
22 -22
Accounts payable
-1,519 -953
Accrued expenses
-1,515 -1,412
Operating lease liability
-522 -538
Net cash used in operating activities
-33,824 -65,848
Purchase of fixed assets
10 21
Proceeds from the sale of property and equipment
3 -
Net cash used in investing activities
-7 -21
Proceeds from the issuance of debt
0 99,965
Payment of fees associated with debt
0 125
Proceeds from the exercise of stock options
352 0
Net cash provided by financing activities
352 99,840
Net increase (decrease) in cash and cash equivalents
-33,479 33,971
Cash and cash equivalents at beginning of period
152,596 -
Cash and cash equivalents at end of period
153,088 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Inhibrx Biosciences, Inc. (INBX)

Inhibrx Biosciences, Inc. (INBX)